IRB #: 20181450 Exp 7/2019

Amryt EASE study opens for recruitment at Amjad Plastic Research, Miami, FL, Raoof Dermatology/Encino Research Center in Encino, CA, and Masonic Children's Hospital, University of Minnesota, Minneapolis.

Amryt, a company focused on developing products that help to improve the lives of patients where there is a high unmet medical need, is pleased to announce that **Dr. Kristen Hook, MD, Masonic Children's Hospital, University of Minnesota, Minneapolis; Dr. Joseph Raoof, Raoof Dermatology/Encino Research Center, Encino, CA; and Ibrahim Amjad, MD, at Amjad Plastic Research, Miami, FL;** are now open to recruit patients with Epidermolysis Bullosa (EB) into the Global EASE study. The EASE study is investigating Oleogel-S10, a topical treatment for the wounds associated with inherited EB.

These locations join **Leslie Castelo-Soccio, MD, Ph.D., Children's Hospital of Philadelphia, Philadelphia, PA; Jordan Slutsky, MD, Stony Brook Dermatology, Stony Brook, NY; Anna Bruckner, MD, Children's Hospital of Colorado in Denver; and John Browning, MD, Texas Dermatology and Laser Specialist in San Antonio,** as study sites for Amryt's ph III trial in EB, EASE. All of these sites are open to recruit eligible patients with Epidermolysis Bullosa (EB) into the global EASE study

Up to 10 trial sites are planned in the US and initiation of these sites is a significant milestone in accelerating patient recruitment into the EASE study. The EASE study has existing trial sites in Europe, Australasia, Latin America and the Middle East. The US Food and Drug Administration ("FDA") granted Investigational New Drug ("IND") clearance for the EASE study in September 2018.

Up to date information about the EASE study, including study design, study site information, and how to contact a site directly is available on clinicaltrials.gov

Additional EASE Trial Updates:
A pre-specified recent interim efficacy analysis occurred when 50% of study patients were enrolled into the EASE study. The purpose of this analysis was to check that sufficient patients were enrolled in the study to detect a difference in the efficacy on wound healing of Oleogel-S10 compared with placebo with adequate statistical power. The recommendation of an independent data monitoring committee (IDMC) was to increase in the number of evaluable subjects in the study from 182 to a total of 230.

An interim safety analysis was also conducted. The IDMC interim safety analysis has recommended that sites can now include enrollment of infants and children with EB between the ages of 21 days to 4 years of age into the trial. The IDMC's interim safety analysis was conducted using pharmacokinetic ("PK") data received from patients already enrolled in the trial (aged four years and older). Amryt will begin the recruitment process for infants and children into EASE immediately. The EASE trial is the largest ever global Phase III study conducted in patients with EB.

Amryt is encouraged by this news. The modest increase in patients required for the study and extending the age eligibility criteria is positive news and a significant step forward in addressing the unmet need in this devastating condition, which is present from birth in most cases. Amryt would like to thank sincerely the patients, families and clinical investigators involved in the EASE trial.